|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
642402250[A06904161]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/10ml/¾ÚÇÃ(2005.04.01)(ÇöÀç¾à°¡)
\3,212 ¿ø/10ml/¾ÚÇÃ(2003.01.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
½É±Ù°æ»ö, ¿Ü»ó, ³»µ¶¼ºÆÐÇ÷Áõ, ¼ö¼úÈÄ¡¤½ÅÀå¾Ö¡¤¸¸¼º½É´ë»óºÎÀüÁõ(¿ïÇ÷¼º½ÉºÎÀü)À¸·Î ÀÎÇÑ ¼ï, ÇÌ´¢, ¹«´¢Áõ, ½É¹ÚÃâ·® °¨¼Ò·Î ÀÎÇÑ ÀúÇ÷¾Ð
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
1. ¿ë·®
¼ºÀÎ : µµÆÄ¹Î¿°»ê¿°À¸·Î¼ üÁß §¸´ç 2-5§¶/ºÐÀ» Á¤¸ÆÁÖ»çÇÑ´Ù. ÁßÁõÀÎ °æ¿ì¿¡´Â üÁß §¸´ç 5-10§¶/ºÐ¿¡¼ 20-50§¶/ºÐ±îÁö Áõ·®ÇÏ¿© Á¤¸ÆÁÖ»çÇÒ ¼ö ÀÖ´Ù.
¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
2. ÀÌ ¾àÀ» Åõ¿©Çϱâ Àü¿¡ Ç÷¾×À̳ª Ç÷ÀåÀ» Åõ¿©ÇÏ¿© Á¤¸Æ¾ÐÀÌ 10-15§¯ H2O, Æó½û±â¾ÐÀÌ 14-18mmHg°¡ µÇµµ·Ï ÇÑ´Ù.
3. üÁß §¸´ç 50§¶/ºÐ ÀÌ»ó Åõ¿©ÇÒ °æ¿ì¿¡´Â ¿ä·® °Ë»ç¸¦ ÀÚÁÖ ÇÑ´Ù.
4. Èñ¼®¿ë¾×
Á¤¸ÆÁÖ»ç½Ã 250§¢ ¶Ç´Â 500§¢ÀÇ ´ÙÀ½ ¿ë¾×¿¡ Èñ¼®ÇÏ¿© »ç¿ëÇÑ´Ù. : »ý¸®½Ä¿°ÁÖ»ç¾×, 5% Æ÷µµ´çÁÖ»ç¾×, 5% Æ÷µµ´ç°¡ 0.9% »ý¸®½Ä¿°ÁÖ»ç¾×, 0.45% »ý¸®½Ä¿°ÁÖ»ç¾×¿¡ ¿ëÇØ½ÃŲ 5% Æ÷µµ´ç, Á¥»êÇÔÀ¯ ¸µ°Ö¾×¿¡ ¿ëÇØ½ÃŲ 5% Æ÷µµ´ç, Á¥»ê³ªÆ®·ýÁÖ»ç¾×, Á¥»êÇÔÀ¯ ¸µ°Ö¾× µî
|
| ÁÖ¿ä¾à¹° »óÈ£ÀÛ¿ë |
[Á¶È¸]
|
| ±Ý±â |
1) Å©·Òģȼ¼Æ÷Á¾ ȯÀÚ
2) ºó¸Æ¼º ºÎÁ¤¸Æ ȯÀÚ
3) ½É½Ç¼¼µ¿ ȯÀÚ
4) °©»ó¼±Áßµ¶Áõ ȯÀÚ
5) Æó¼â¿ì°¢Çü³ì³»Àå ȯÀÚ
|
| ½ÅÁßÅõ¿© |
1) ¸»ÃÊÇ÷°üÀå¾Ö ȯÀÚ(´ç´¢º´, ¾ËÄÚ¿ÃÁßµ¶, µ¿»ó, µ¿¸Æ°æÈÁõ, ·¹À̳ëÁõÈıº, ¹ö°Åº´ µî)
2) ÀÌ ¾àÀº ¾ÆÈ²»ê¼ö¼Ò³ªÆ®·ýÀÌ ÇÔÀ¯µÇ¾î ÀÖ¾î ¾Æ³ªÇʶô½Ã¿Í °°Àº ¾Ë·¹¸£±â¸¦ ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¸ç ÀϺΠ°¨¼ö¼º ȯÀÚ¿¡¼´Â »ý¸íÀ» À§ÇùÇÒ Á¤µµ ¶Ç´Â À̺¸´Ù ¾àÇÑ Ãµ½Ä¹ßÀÛÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù. ÀÏ¹Ý »ç¶÷¿¡¼ÀÇ ¾ÆÈ²»ê°¨¼ö¼º¿¡ ´ëÇÑ ÃѰýÀûÀÎ ºóµµ´Â ¾Ë·ÁÁöÁö ¾Ê¾ÒÀ¸³ª ³·Àº °ÍÀ¸·Î º¸ÀÌ¸ç ¾ÆÈ²»ê°¨¼ö¼ºÀº ºñõ½ÄȯÀÚº¸´Ù õ½ÄȯÀÚ¿¡¼ ºó¹øÇÑ °ÍÀ¸·Î ³ªÅ¸³µ´Ù.
|
| ÀÌ»ó¹ÝÀÀ |
1) ¼øÈ¯±â°è
¨ç ½É½Ç¼º ±â¿Ü¼öÃà, ½É¹æ¼¼µ¿ ¹× ½É½Çºó¸Æ µîÀÇ ºÎÁ¤¸ÆÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î °üÂûÀ» ÃæºÐÈ÷ Çϰí ÀÌ»óÀÌ ÀÎÁ¤µÇ´Â °æ¿ì¿¡´Â ºÎÁ¤¸Æ¿ëÁ¦¸¦ Åõ¿©Çϰųª Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
¨è ¸»ÃÊÇ÷°ü¼öÃàÀ¸·Î ¸»ÃÊÀÇ ÇãÇ÷ÀÌ ÀϾ ¼ö ÀÖÀ¸¹Ç·Î »çÁöÀÇ »ö ¹× ¿Âµµ¸¦ ÃæºÐÈ÷ °üÂûÇÏ°í º¯È°¡ ³ªÅ¸³¯ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÇÊ¿äÇÏ´Ù¸é ¥á-Â÷´ÜÁ¦¸¦ Åõ¿©ÇÑ´Ù.
¨é ºó¸Æ, Çù½ÉÁõ, ½É°èÇ×Áø, È£Èí°ï¶õ, ÀúÇ÷¾Ð, ¸Å¿ì µå¹°°Ô ÀÌ»óÀüµµ, ¼¸Æ, QRSÆø Áõ´ë, °íÁú¼ÒÇ÷Áõ, Ç÷¾Ð»ó½Â µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
2) ¼Òȱâ°è : ¶§¶§·Î ±¸¿ª, ±¸Åä, º¹ºÎÆØ¸¸, º¹Åë, µå¹°°Ô ¸¶ºñ¼º ÀåÆó»öÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
3) ±âŸ : ¶§¶§·Î µÎÅë, ºÒ¾È, µå¹°°Ô Á¤¸Æ¿°, ÁÖ»çºÎÀ§ÀÇ º¯¼º ±«»ç ¹× ÀԸ𰡠³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
1) ½ÃŬ·ÎÇÁ·ÎÆÇÀ̳ª ÇҷΰÕÈ ÅºÈ¼ö¼Ò°è ¸¶ÃëÁ¦¿Í º´¿ëÅõ¿©½Ã ½ÉÀåÀ» ÀڱؽÃŰ¹Ç·Î ƯÈ÷ ÁÖÀÇÇÑ´Ù.
2) MAOÀúÇØÁ¦ Åõ¿©½Ã¿¡´Â ÀÌ ¾à Åõ¿©Àü¿¡ ¿ë·®À» °¨¼Ò(ÃÊȸ·®À» »ó¿ë·®ÀÇ 1/10)½ÃŲ´Ù. ÀÌ ¾àÀº MAO¿¡ ÀÇÇØ ´ë»çµÇ°í MAOÀúÇØÁ¦´Â MAO¸¦ ¾ïÁ¦ÇϹǷΠȿ°ú¸¦ Áõ°½ÃŲ´Ù.
3) Æä³ëÄ¡¾ÆÁø°è ¾à¹° ¹× ºÎÄ¡·ÎÆæ°è ¾à¹°°ú º´¿ëÅõ¿©½Ã ½Åµ¿¸ÆÇ÷·ùÁõ°¡ µîÀÇ ¹ÝÀÀÀÌ °¨¼ÒÇÒ ¼ö ÀÖ´Ù.
4) ±¸¾Æ³×Ƽµò, »ïȯ°è Ç׿ì¿ïÁ¦, ·¹¼¼¸£ÇÉ, ±³°¨½Å°æÈ¿´É¾à, °©»ó¼±È£¸£¸ó, Ç×È÷½ºÅ¸¹ÎÁ¦¿Í º´¿ëÅõ¿©½Ã ±³°¨½Å°æÈïºÐÀÛ¿ëÀÌ Áõ°µÉ ¼ö ÀÖ´Ù.
5) ¥á,¥â-Â÷´ÜÁ¦¿Í º´¿ëÅõ¿©½Ã Ç÷¾Ð°ÇÏ ¹× »ó½ÂÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
(ÀӺο¡ ´ëÇÑ Ä¡·á ÀÌÀÍÀÌ Å¾ƿ¡ ´ëÇÑ À§Ç輺À» »óȸÇÒ °æ¿ì¿¡ ÇÑÇØ »ç¿ëÇÒ °Í. -Briggs G, et al. Drugs in Pregnancy and Lactation 7th edit. )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Dopamine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Dopamine is a precursor to norepinephrine in noradrenergic nerves and is also a neurotransmitter in certain areas of the central nervous system. Dopamine produces positive chronotropic and inotropic effects on the myocardium, resulting in increased heart rate and cardiac contractility. This is accomplished directly by exerting an agonist action on beta-adrenoceptors and indirectly by causing release of norepinephrine from storage sites in sympathetic nerve endings.
|
| Pharmacology |
Dopamine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Dopamine is a natural catecholamine formed by the decarboxylation of 3,4-dihydroxyphenylalanine (DOPA). It is a precursor to norepinephrine in noradrenergic nerves and is also a neurotransmitter in certain areas of the central nervous system, especially in the nigrostriatal tract, and in a few peripheral sympathetic nerves. Dopamine produces positive chronotropic and inotropic effects on the myocardium, resulting in increased heart rate and cardiac contractility. This is accomplished directly by exerting an agonist action on beta-adrenoceptors and indirectly by causing release of norepinephrine from storage sites in sympathetic nerve endings.
|
| Metabolism |
Dopamine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Monoamine oxidase type A (MAO-A)Monoamine oxidase type B (MAO-B)Catechol O-methyltransferase (COMT)
|
| Protein Binding |
Dopamine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ No information currently available on protein binding.
|
| Half-life |
Dopamine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 2 minutes
|
| Absorption |
Dopamine¿¡ ´ëÇÑ Absorption Á¤º¸ Dopamine is rapidly absorbed from the small intestine.
|
| Biotransformation |
Dopamine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Biotransformation of dopamine proceeds rapidly to yield the principal excretion products, 3-4-dihydroxy-phenylacetic acid (DOPAC) and 3-methoxy-4-hydroxy-phenylacetic acid (homovanillic acid, HVA).
|
| Toxicity |
Dopamine¿¡ ´ëÇÑ Toxicity Á¤º¸ LD50 oral mice = 1460 mg/kg, LD50 oral rats = 1780 mg/kg. Spasm or closing of eyelids, nausea, vomiting, cardiac arrhythmias, involuntary movements of the body including the face, tongue, arms, hand, head, and upper body; hypotension, haemolytic anaemia, urinary retention, duodenal ulcer, sialorrhea, ataxia, abdominal pain, dry mouth, nightmares, tachypnoea, bruxism, confusion, and insomnia.
|
| Drug Interactions |
Dopamine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Dopamine¿¡ ´ëÇÑ Description Á¤º¸ One of the catecholamine neurotransmitters in the brain. It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (receptors, dopamine) mediate its action. [PubChem]
|
| Drug Category |
Dopamine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Cardiotonic AgentsDopamine AgentsSympathomimeticSympathomimetics
|
| Smiles String Canonical |
Dopamine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ NCCC1=CC(O)=C(O)C=C1
|
| Smiles String Isomeric |
Dopamine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ NCCC1=CC(O)=C(O)C=C1
|
| InChI Identifier |
Dopamine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C8H11NO2/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,10-11H,3-4,9H2
|
| Chemical IUPAC Name |
Dopamine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 4-(2-aminoethyl)benzene-1,2-diol
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2024-07-24
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|